Search Results

There are 8412218 results for: content related to: PROLONGED SURVIVAL IN RENAL TRANSPLANT RECIPIENT WITH ADVANCED RENAL CELL CARCINOMA BY EVEROLIMUS AND SORAFENIB

  1. You have free access to this content
    A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma

    Cancer

    Volume 117, Issue 18, 15 September 2011, Pages: 4194–4200, Andrea L. Harzstark, Eric J. Small, Vivian K. Weinberg, Janine Sun, Charles J. Ryan, Amy M. Lin, Lawrence Fong, Dion R. Brocks and Jonathan E. Rosenberg

    Version of Record online : 8 MAR 2011, DOI: 10.1002/cncr.25931

  2. You have free access to this content
    Mechanisms of Everolimus-Induced Glomerulosclerosis After Glomerular Injury in the Rat

    American Journal of Transplantation

    Volume 5, Issue 12, December 2005, Pages: 2849–2861, C. Daniel, L. Renders, K. Amann, E. Schulze-Lohoff, I.A. Hauser and C. Hugo

    Version of Record online : 18 NOV 2005, DOI: 10.1111/j.1600-6143.2005.01120.x

  3. You have full text access to this OnlineOpen article
    Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma – systematic review and meta-analysis

    Cancer Medicine

    Volume 2, Issue 6, December 2013, Pages: 862–871, Kenya Yamanaka, Marius Petrulionis, Shibo Lin, Chao Gao, Uwe Galli, Susanne Richter, Susanne Winkler, Philipp Houben, Daniel Schultze, Etsuro Hatano and Peter Schemmer

    Version of Record online : 22 OCT 2013, DOI: 10.1002/cam4.150

  4. Everolimus: A Proliferation Signal Inhibitor with Clinical Applications in Organ Transplantation, Oncology, and Cardiology

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 30, Issue 10, October 2010, Pages: 1044–1056, Steven Gabardi and Steven A. Baroletti

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.30.10.1044

  5. Blood Concentrations of Everolimus Are Markedly Increased by Ketoconazole

    The Journal of Clinical Pharmacology

    Volume 45, Issue 5, May 2005, Pages: 514–528, Dr J. M. Kovarik, Dr D. Beyer, Dr M. N. Bizot, Dr Q. Jiang, Dr M. Shenouda and Dr R. L. Schmouder

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270005275368

  6. You have free access to this content
    Everolimus Plus Reduced-Exposure CsA versus Mycophenolic Acid Plus Standard-Exposure CsA in Renal-Transplant Recipients

    American Journal of Transplantation

    Volume 10, Issue 6, June 2010, Pages: 1401–1413, H. Tedesco Silva Jr., D. Cibrik, T. Johnston, E. Lackova, K. Mange, C. Panis, R. Walker, Z. Wang, G. Zibari and Y. S. Kim

    Version of Record online : 28 APR 2010, DOI: 10.1111/j.1600-6143.2010.03129.x

  7. You have free access to this content
    Phase 3 trial of everolimus for metastatic renal cell carcinoma

    Cancer

    Volume 116, Issue 18, 15 September 2010, Pages: 4256–4265, Robert J. Motzer, Bernard Escudier, Stephane Oudard, Thomas E. Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, John A. Thompson, Robert A. Figlin, Norbert Hollaender, Andrea Kay, Alain Ravaud and for the RECORD-1 Study Group

    Version of Record online : 19 AUG 2010, DOI: 10.1002/cncr.25219

  8. Influence of Everolimus on Steady-State Pharmacokinetics of Cyclosporine in Maintenance Renal Transplant Patients

    The Journal of Clinical Pharmacology

    Volume 45, Issue 7, July 2005, Pages: 781–791, Dr Klemens Budde, Dr Gustav Lehne, Dr Michael Winkler, Dr Lutz Renders, Dr Arno Lison, Dr Lutz Fritsche, Dr Jean-Paul Soulillou, Dr Per Fauchald, Dr Hans-Hellmut Neumayer, Dr Jaques Dantal and Behalf of the RADW 102 Renal Transplant Study Group

    Version of Record online : 25 MAR 2013, DOI: 10.1177/0091270005277196

  9. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine

    Clinical Pharmacology & Therapeutics

    Volume 69, Issue 1, January 2001, Pages: 48–56, John M. Kovarik, Barry D. Kahan, Bruce Kaplan, Marc Lorber, Michael Winkler, Marisel Rouilly, Christophe Gerbeau, Natalie Cambon, Robert Boger, Christiane Rordorf and on behalf of the Everolimus Phase 2 Study Group

    Version of Record online : 5 JAN 2001, DOI: 10.1067/mcp.2001.112969

  10. You have free access to this content
    Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation

    Transplant International

    Volume 28, Issue 1, January 2015, Pages: 42–51, Lars Mjörnstedt, Søren Schwartz Sørensen, Bengt von zur Mühlen, Bente Jespersen, Jesper M. Hansen, Claus Bistrup, Helene Andersson, Bengt Gustafsson, Dag Solbu and Hallvard Holdaas

    Version of Record online : 30 SEP 2014, DOI: 10.1111/tri.12437

  11. You have free access to this content
    Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain

    Liver Transplantation

    Volume 21, Issue 8, August 2015, Pages: 1056–1065, Itxarone Bilbao, Magdalena Salcedo, Miguel Angel Gómez, Carlos Jimenez, Javier Castroagudín, Joan Fabregat, Carolina Almohalla, Ignacio Herrero, Valentín Cuervas-Mons, Alejandra Otero, Angel Rubín, Manuel Miras, Juan Rodrigo, Trinidad Serrano, Gonzalo Crespo, Manuel De la Mata, Javier Bustamante, M. Luisa Gonzalez-Dieguez, Antonia Moreno, Isidoro Narvaez, Magda Guilera and for the EVEROLIVER study group

    Version of Record online : 24 JUL 2015, DOI: 10.1002/lt.24172

  12. You have free access to this content
    Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use

    BJU International

    Volume 107, Issue 11, June 2011, Pages: 1722–1732, Ziya Kirkali

    Version of Record online : 20 JAN 2011, DOI: 10.1111/j.1464-410X.2010.09985.x

  13. You have free access to this content
    Everolimus Versus Mycophenolate Mofetil in Heart Transplantation: A Randomized, Multicenter Trial

    American Journal of Transplantation

    Volume 13, Issue 5, May 2013, Pages: 1203–1216, H. J. Eisen, J. Kobashigawa, R. C. Starling, D. F. Pauly, A. Kfoury, H. Ross, S.-S. Wang, B. Cantin, A. Van Bakel, G. Ewald, S. Hirt, H. Lehmkuhl, A. Keogh, M. Rinaldi, L. Potena, A. Zuckermann, G. Dong, C. Cornu-Artis and P. Lopez

    Version of Record online : 22 FEB 2013, DOI: 10.1111/ajt.12181

  14. You have free access to this content
    Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma

    Cancer

    Volume 118, Issue 7, 1 April 2012, Pages: 1868–1876, Ana M. Molina, Darren R. Feldman, Martin H. Voss, Michelle S. Ginsberg, Michael S. Baum, Dion R. Brocks, Patricia M. Fischer, Michael J. Trinos, Sujata Patil and Robert J. Motzer

    Version of Record online : 6 SEP 2011, DOI: 10.1002/cncr.26429

  15. Phase Ib of Sorafenib in Combination With Everolimus in Patients With Advanced Solid Tumors, Selected on the Basis of Molecular Targets

    The Oncologist

    Volume 19, Issue 4, April 2014, Pages: 344–345, Francesca Toffalorio, Gianluca Spitaleri, Chiara Catania, Laura Dal Zotto, Cristina Noberasco, Angelo Delmonte, Mariacarmela Santarpia, Fabio Vecchio, Veronica Brunelli, Cristiano Rampinelli, Massimo Barberis, Caterina Fumagalli, Massimo Zucchetti, Monique Zangarini, Tullia Diena, Romano Danesi, Filippo de Braud and Tommaso De Pas

    Version of Record online : 27 MAR 2014, DOI: 10.1634/theoncologist.2013-0335

  16. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases

    Annals of the New York Academy of Sciences

    Volume 1291, Issue 1, July 2013, Pages: 14–32, David Lebwohl, Özlem Anak, Tarek Sahmoud, Judith Klimovsky, Ingrid Elmroth, Tomas Haas, Joseph Posluszny, Stephen Saletan and William Berg

    Version of Record online : 9 MAY 2013, DOI: 10.1111/nyas.12122

  17. You have free access to this content
    Improved Renal Function After Early Conversion From a Calcineurin Inhibitor to Everolimus: a Randomized Trial in Kidney Transplantation

    American Journal of Transplantation

    Volume 12, Issue 10, October 2012, Pages: 2744–2753, L. Mjörnstedt, S. S. Sørensen, B. von zur Mühlen, B. Jespersen, J. M. Hansen, C. Bistrup, H. Andersson, B. Gustafsson, L.H. Undset, H. Fagertun, D. Solbu and H. Holdaas

    Version of Record online : 19 JUL 2012, DOI: 10.1111/j.1600-6143.2012.04162.x

  18. You have free access to this content
    Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3-Year Results From the Randomized ZEUS Study

    American Journal of Transplantation

    Volume 12, Issue 6, June 2012, Pages: 1528–1540, K. Budde, F. Lehner, C. Sommerer, W. Arns, P. Reinke, U. Eisenberger, R. P. Wüthrich, S. Scheidl, C. May, E.-M. Paulus, A. Mühlfeld, H. H. Wolters, K. Pressmar, R. Stahl, O. Witzke and On behalf of the ZEUS Study Investigators

    Version of Record online : 5 MAR 2012, DOI: 10.1111/j.1600-6143.2012.03994.x

    Corrected by:

    Erratum

    Vol. 12, Issue 11, 3165, Version of Record online: 27 OCT 2012

  19. You have free access to this content
    Three-Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients

    American Journal of Transplantation

    Volume 5, Issue 10, October 2005, Pages: 2521–2530, Štefan Vítko, Raimund Margreiter, Willem Weimar, Jacques Dantal, Dirk Kuypers, Michael Winkler, Ole Øyen, Hendrik G. Viljoen, Pavel Filiptsev, Sami Sadek, Yulan Li, Nathalie Cretin, Klemens Budde and for the RAD B201 Study Group

    Version of Record online : 11 SEP 2005, DOI: 10.1111/j.1600-6143.2005.01063.x

  20. You have free access to this content
    AMERICAN TRANSPLANT CONGRESS 2012 ABSTRACTS

    American Journal of Transplantation

    Volume 12, Issue s3, May 2012, Pages: 27–542,

    Version of Record online : 26 APR 2012, DOI: 10.1111/j.1600-6143.2012.04112.x